| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 58 | 2021 | 7782 | 4.650 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 16 | 2021 | 382 | 2.570 |
Why?
|
| Contrast Media | 27 | 2019 | 1498 | 2.440 |
Why?
|
| Adrenal Gland Neoplasms | 12 | 2024 | 527 | 2.390 |
Why?
|
| Perfusion Imaging | 8 | 2018 | 32 | 2.020 |
Why?
|
| Neuroendocrine Tumors | 8 | 2019 | 655 | 1.870 |
Why?
|
| Liver Neoplasms | 23 | 2019 | 4820 | 1.700 |
Why?
|
| Liver | 9 | 2018 | 3089 | 1.250 |
Why?
|
| Radiographic Image Enhancement | 8 | 2019 | 410 | 1.130 |
Why?
|
| Image Enhancement | 6 | 2015 | 553 | 1.120 |
Why?
|
| Kidney Neoplasms | 20 | 2018 | 3107 | 1.080 |
Why?
|
| Neovascularization, Pathologic | 7 | 2019 | 1585 | 1.030 |
Why?
|
| Artifacts | 6 | 2018 | 536 | 0.970 |
Why?
|
| Diagnostic Imaging | 6 | 2017 | 1174 | 0.950 |
Why?
|
| Carcinoma, Renal Cell | 18 | 2018 | 2388 | 0.940 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2015 | 7893 | 0.800 |
Why?
|
| Gadolinium DTPA | 4 | 2011 | 173 | 0.780 |
Why?
|
| Aged | 86 | 2021 | 73338 | 0.750 |
Why?
|
| Carcinoid Tumor | 4 | 2015 | 282 | 0.730 |
Why?
|
| Interferon-alpha | 6 | 2013 | 959 | 0.730 |
Why?
|
| Lung Neoplasms | 12 | 2018 | 12024 | 0.720 |
Why?
|
| Reproducibility of Results | 18 | 2018 | 6191 | 0.700 |
Why?
|
| Everolimus | 4 | 2018 | 436 | 0.680 |
Why?
|
| Middle Aged | 92 | 2024 | 90294 | 0.670 |
Why?
|
| Bevacizumab | 9 | 2018 | 966 | 0.660 |
Why?
|
| Abdomen, Acute | 2 | 2010 | 38 | 0.650 |
Why?
|
| Sensitivity and Specificity | 18 | 2018 | 5171 | 0.630 |
Why?
|
| Male | 102 | 2021 | 128316 | 0.620 |
Why?
|
| Triiodobenzoic Acids | 4 | 2012 | 69 | 0.620 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 73 | 0.620 |
Why?
|
| Positron-Emission Tomography | 10 | 2017 | 2196 | 0.610 |
Why?
|
| Blood Flow Velocity | 8 | 2015 | 542 | 0.600 |
Why?
|
| Adult | 73 | 2024 | 81946 | 0.590 |
Why?
|
| Adrenal Gland Diseases | 2 | 2015 | 70 | 0.580 |
Why?
|
| Liver Circulation | 2 | 2015 | 36 | 0.560 |
Why?
|
| Patient Positioning | 2 | 2018 | 196 | 0.560 |
Why?
|
| Female | 99 | 2021 | 148865 | 0.550 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2010 | 999 | 0.540 |
Why?
|
| Frail Elderly | 4 | 2007 | 124 | 0.500 |
Why?
|
| Colonography, Computed Tomographic | 2 | 2007 | 55 | 0.490 |
Why?
|
| Histoplasmosis | 1 | 2015 | 77 | 0.490 |
Why?
|
| Humans | 127 | 2024 | 270631 | 0.490 |
Why?
|
| Neoplasm Staging | 22 | 2017 | 14009 | 0.470 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2018 | 1266 | 0.470 |
Why?
|
| Aorta | 1 | 2018 | 670 | 0.460 |
Why?
|
| Neoplasms | 17 | 2021 | 15909 | 0.460 |
Why?
|
| Acute Kidney Injury | 2 | 2018 | 760 | 0.440 |
Why?
|
| Carboplatin | 1 | 2017 | 879 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 24 | 2016 | 16664 | 0.440 |
Why?
|
| Blood Volume | 4 | 2015 | 107 | 0.440 |
Why?
|
| Candidiasis | 1 | 2015 | 278 | 0.420 |
Why?
|
| Aged, 80 and over | 34 | 2019 | 30994 | 0.420 |
Why?
|
| Retrospective Studies | 32 | 2024 | 39811 | 0.400 |
Why?
|
| Creatinine | 3 | 2010 | 529 | 0.400 |
Why?
|
| Algorithms | 6 | 2019 | 3900 | 0.390 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2018 | 880 | 0.390 |
Why?
|
| Hepatic Artery | 6 | 2015 | 256 | 0.390 |
Why?
|
| Liver Function Tests | 1 | 2011 | 185 | 0.370 |
Why?
|
| Diagnosis, Differential | 8 | 2019 | 4829 | 0.370 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 477 | 0.360 |
Why?
|
| Pulmonary Circulation | 1 | 2011 | 132 | 0.360 |
Why?
|
| Ureteral Neoplasms | 2 | 2010 | 238 | 0.360 |
Why?
|
| Adrenalectomy | 4 | 2018 | 195 | 0.360 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 120 | 0.360 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2018 | 1260 | 0.340 |
Why?
|
| Adrenal Cortex Neoplasms | 3 | 2024 | 242 | 0.340 |
Why?
|
| Oxygen Radioisotopes | 1 | 2009 | 7 | 0.340 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 2 | 2020 | 57 | 0.340 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2019 | 1688 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 8 | 2020 | 5254 | 0.310 |
Why?
|
| Liver Diseases | 2 | 2011 | 602 | 0.300 |
Why?
|
| Ovarian Neoplasms | 5 | 2017 | 4790 | 0.300 |
Why?
|
| Abdominal Cavity | 1 | 2007 | 23 | 0.300 |
Why?
|
| Antineoplastic Agents | 16 | 2018 | 14616 | 0.300 |
Why?
|
| Iodine | 2 | 2018 | 55 | 0.290 |
Why?
|
| Neoplasm Metastasis | 12 | 2015 | 5309 | 0.290 |
Why?
|
| Radiography, Abdominal | 1 | 2008 | 126 | 0.290 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2024 | 191 | 0.290 |
Why?
|
| Water | 1 | 2009 | 388 | 0.280 |
Why?
|
| Prognosis | 11 | 2017 | 22473 | 0.280 |
Why?
|
| Immunologic Factors | 2 | 2013 | 672 | 0.280 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2009 | 2431 | 0.270 |
Why?
|
| Biomarkers | 2 | 2015 | 5060 | 0.270 |
Why?
|
| Sirolimus | 4 | 2016 | 831 | 0.270 |
Why?
|
| Indoles | 4 | 2015 | 1028 | 0.270 |
Why?
|
| Young Adult | 18 | 2021 | 22201 | 0.260 |
Why?
|
| Radiopharmaceuticals | 4 | 2018 | 1341 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 7 | 2011 | 4480 | 0.250 |
Why?
|
| Polyglutamic Acid | 3 | 2011 | 49 | 0.250 |
Why?
|
| Child Abuse | 2 | 1998 | 208 | 0.240 |
Why?
|
| Kidney Diseases | 1 | 2010 | 693 | 0.240 |
Why?
|
| Paraganglioma | 1 | 2007 | 200 | 0.240 |
Why?
|
| Kidney | 2 | 2010 | 2119 | 0.240 |
Why?
|
| Glioma | 2 | 2015 | 1977 | 0.240 |
Why?
|
| Disabled Persons | 2 | 2004 | 110 | 0.240 |
Why?
|
| Area Under Curve | 5 | 2015 | 729 | 0.240 |
Why?
|
| Colorectal Neoplasms | 5 | 2010 | 3707 | 0.240 |
Why?
|
| Predictive Value of Tests | 10 | 2021 | 4962 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2021 | 3408 | 0.230 |
Why?
|
| Rats, Nude | 2 | 2015 | 28 | 0.230 |
Why?
|
| Melanoma | 9 | 2012 | 5594 | 0.230 |
Why?
|
| Computed Tomography Angiography | 2 | 2016 | 247 | 0.230 |
Why?
|
| Angiography | 2 | 2015 | 350 | 0.220 |
Why?
|
| Pheochromocytoma | 2 | 2019 | 310 | 0.220 |
Why?
|
| Tumor Burden | 4 | 2018 | 2033 | 0.210 |
Why?
|
| Cecal Neoplasms | 1 | 2002 | 4 | 0.210 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2024 | 143 | 0.210 |
Why?
|
| Sample Size | 2 | 2015 | 213 | 0.200 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2011 | 743 | 0.200 |
Why?
|
| Disease-Free Survival | 14 | 2017 | 10258 | 0.200 |
Why?
|
| Treatment Outcome | 33 | 2021 | 33722 | 0.190 |
Why?
|
| Adrenal Glands | 2 | 2018 | 131 | 0.190 |
Why?
|
| Prospective Studies | 9 | 2018 | 13412 | 0.190 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2019 | 361 | 0.190 |
Why?
|
| Models, Statistical | 2 | 2019 | 1185 | 0.190 |
Why?
|
| Benzenesulfonates | 3 | 2012 | 196 | 0.180 |
Why?
|
| Carcinoma | 2 | 2002 | 2609 | 0.180 |
Why?
|
| Retroperitoneal Space | 2 | 2018 | 156 | 0.180 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 248 | 0.180 |
Why?
|
| Pyridines | 4 | 2012 | 1311 | 0.170 |
Why?
|
| Pyrroles | 2 | 2015 | 589 | 0.170 |
Why?
|
| Abdominal Pain | 1 | 2002 | 378 | 0.170 |
Why?
|
| Radiography | 4 | 2015 | 1986 | 0.160 |
Why?
|
| Genes, ras | 2 | 2012 | 679 | 0.160 |
Why?
|
| Abdomen | 1 | 2020 | 349 | 0.160 |
Why?
|
| Rib Fractures | 1 | 1998 | 38 | 0.160 |
Why?
|
| Observer Variation | 2 | 2018 | 709 | 0.160 |
Why?
|
| Fluorouracil | 6 | 2013 | 1989 | 0.150 |
Why?
|
| Iohexol | 1 | 2018 | 56 | 0.150 |
Why?
|
| Thalidomide | 2 | 2015 | 595 | 0.150 |
Why?
|
| Lifting | 1 | 1997 | 3 | 0.150 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2012 | 622 | 0.150 |
Why?
|
| Rare Diseases | 1 | 2021 | 358 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 8 | 2016 | 1320 | 0.150 |
Why?
|
| Decision Trees | 1 | 2018 | 181 | 0.150 |
Why?
|
| Abdominal Injuries | 1 | 1998 | 122 | 0.150 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4326 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2017 | 5070 | 0.140 |
Why?
|
| Viscera | 1 | 1997 | 92 | 0.140 |
Why?
|
| Paclitaxel | 2 | 2017 | 2100 | 0.140 |
Why?
|
| Medical Staff, Hospital | 1 | 1997 | 122 | 0.140 |
Why?
|
| Skin Neoplasms | 5 | 2012 | 4889 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2015 | 10383 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 1997 | 131 | 0.140 |
Why?
|
| Workflow | 1 | 2018 | 277 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 985 | 0.130 |
Why?
|
| Adenoma | 2 | 2019 | 739 | 0.130 |
Why?
|
| Disease Progression | 6 | 2021 | 6853 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2018 | 293 | 0.130 |
Why?
|
| Rats | 3 | 2015 | 6524 | 0.130 |
Why?
|
| Deoxycytidine | 5 | 2013 | 1389 | 0.130 |
Why?
|
| Laparoscopy | 2 | 2018 | 1301 | 0.130 |
Why?
|
| Time Factors | 8 | 2021 | 13017 | 0.130 |
Why?
|
| Myelolipoma | 1 | 2015 | 13 | 0.130 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2019 | 1642 | 0.130 |
Why?
|
| Whole Body Imaging | 1 | 2016 | 120 | 0.120 |
Why?
|
| Permeability | 1 | 2015 | 160 | 0.120 |
Why?
|
| Adrenal Hyperplasia, Congenital | 1 | 2015 | 43 | 0.120 |
Why?
|
| Niacinamide | 4 | 2012 | 427 | 0.120 |
Why?
|
| Subtraction Technique | 2 | 2015 | 143 | 0.120 |
Why?
|
| Motion | 2 | 2016 | 200 | 0.120 |
Why?
|
| Pyrimidines | 3 | 2015 | 3666 | 0.120 |
Why?
|
| Perfusion | 1 | 2015 | 285 | 0.120 |
Why?
|
| Diagnostic Errors | 2 | 2010 | 517 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2012 | 5403 | 0.120 |
Why?
|
| Taxoids | 4 | 2012 | 1015 | 0.120 |
Why?
|
| Scrotum | 1 | 2014 | 59 | 0.120 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 206 | 0.120 |
Why?
|
| Survival Analysis | 7 | 2014 | 9290 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2015 | 1933 | 0.110 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 147 | 0.110 |
Why?
|
| Valproic Acid | 1 | 2015 | 274 | 0.110 |
Why?
|
| Drug Administration Schedule | 8 | 2016 | 3529 | 0.110 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10701 | 0.110 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 1330 | 0.110 |
Why?
|
| Statistics as Topic | 2 | 2015 | 453 | 0.110 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 15204 | 0.110 |
Why?
|
| Inpatients | 1 | 2018 | 686 | 0.110 |
Why?
|
| Linear Models | 2 | 2013 | 1097 | 0.110 |
Why?
|
| Boronic Acids | 1 | 2014 | 354 | 0.110 |
Why?
|
| Snake Venoms | 1 | 2012 | 8 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 396 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 585 | 0.100 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 591 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 2014 | 183 | 0.100 |
Why?
|
| ROC Curve | 1 | 2015 | 1249 | 0.100 |
Why?
|
| Metformin | 1 | 2016 | 393 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 624 | 0.100 |
Why?
|
| Neoplasms, Experimental | 1 | 2015 | 784 | 0.100 |
Why?
|
| Portal Vein | 2 | 2004 | 363 | 0.100 |
Why?
|
| Decision Making | 2 | 2010 | 1249 | 0.100 |
Why?
|
| Pyrazines | 1 | 2014 | 510 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2010 | 235 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2011 | 374 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1335 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2011 | 1838 | 0.100 |
Why?
|
| Pentetic Acid | 1 | 2011 | 49 | 0.090 |
Why?
|
| Multimodal Imaging | 2 | 2012 | 550 | 0.090 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 5100 | 0.090 |
Why?
|
| Prostatic Neoplasms | 4 | 2010 | 5857 | 0.090 |
Why?
|
| Critical Care | 1 | 2017 | 799 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2010 | 2175 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 537 | 0.090 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2011 | 154 | 0.090 |
Why?
|
| Survival Rate | 7 | 2015 | 12518 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2017 | 735 | 0.090 |
Why?
|
| Movement | 2 | 2011 | 562 | 0.090 |
Why?
|
| Farnesol | 1 | 2010 | 16 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 3027 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2011 | 4960 | 0.090 |
Why?
|
| Salicylates | 1 | 2010 | 73 | 0.090 |
Why?
|
| Infusions, Intravenous | 5 | 2013 | 1437 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2017 | 920 | 0.090 |
Why?
|
| Hexanones | 1 | 2009 | 10 | 0.080 |
Why?
|
| Albumins | 1 | 2011 | 263 | 0.080 |
Why?
|
| Adolescent | 12 | 2018 | 32719 | 0.080 |
Why?
|
| Farnesyltranstransferase | 1 | 2009 | 125 | 0.080 |
Why?
|
| Gadolinium | 1 | 2010 | 169 | 0.080 |
Why?
|
| X-Ray Microtomography | 1 | 2010 | 136 | 0.080 |
Why?
|
| Isotope Labeling | 1 | 2009 | 149 | 0.080 |
Why?
|
| Anilides | 1 | 2011 | 294 | 0.080 |
Why?
|
| Quinolones | 1 | 2009 | 163 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2014 | 1579 | 0.080 |
Why?
|
| Arsenicals | 1 | 2009 | 205 | 0.080 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2021 | 164 | 0.080 |
Why?
|
| Bayes Theorem | 3 | 2019 | 1058 | 0.080 |
Why?
|
| Interleukin-2 | 1 | 2012 | 889 | 0.080 |
Why?
|
| Urethral Neoplasms | 1 | 2008 | 62 | 0.080 |
Why?
|
| Mitotane | 1 | 2007 | 41 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1737 | 0.070 |
Why?
|
| Curcumin | 1 | 2008 | 119 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 517 | 0.070 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 678 | 0.070 |
Why?
|
| Pneumonia | 1 | 2013 | 796 | 0.070 |
Why?
|
| Benzamides | 2 | 2010 | 1878 | 0.070 |
Why?
|
| Cohort Studies | 7 | 2017 | 9471 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2014 | 5231 | 0.070 |
Why?
|
| Hepatic Veins | 2 | 2004 | 59 | 0.070 |
Why?
|
| Glutathione | 1 | 2009 | 375 | 0.070 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2007 | 80 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2010 | 606 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2007 | 94 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2015 | 4117 | 0.070 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2011 | 175 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2015 | 1609 | 0.070 |
Why?
|
| Pentostatin | 1 | 2006 | 121 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2014 | 2376 | 0.060 |
Why?
|
| Postoperative Complications | 2 | 2018 | 5672 | 0.060 |
Why?
|
| Tomography, Spiral Computed | 1 | 2006 | 128 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 2344 | 0.060 |
Why?
|
| Eye Diseases | 1 | 2006 | 129 | 0.060 |
Why?
|
| Respiration | 1 | 2007 | 465 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2007 | 248 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 645 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2012 | 2399 | 0.060 |
Why?
|
| Eye | 1 | 2006 | 283 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2010 | 1232 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 859 | 0.060 |
Why?
|
| Remission Induction | 4 | 2013 | 3652 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 14833 | 0.060 |
Why?
|
| Organoplatinum Compounds | 3 | 2012 | 704 | 0.060 |
Why?
|
| Neutropenia | 1 | 2008 | 1007 | 0.060 |
Why?
|
| Animals | 7 | 2015 | 62031 | 0.060 |
Why?
|
| Macrophages | 1 | 2010 | 1351 | 0.060 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 318 | 0.060 |
Why?
|
| Hydrolases | 1 | 2004 | 132 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2012 | 3553 | 0.050 |
Why?
|
| Capecitabine | 3 | 2010 | 390 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6253 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7235 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2008 | 4963 | 0.050 |
Why?
|
| Phenylurea Compounds | 3 | 2012 | 600 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 841 | 0.050 |
Why?
|
| Breast Neoplasms | 4 | 2014 | 16204 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2006 | 742 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2004 | 282 | 0.050 |
Why?
|
| Thyroid Neoplasms | 2 | 2011 | 1884 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2650 | 0.050 |
Why?
|
| Spleen | 1 | 2004 | 726 | 0.050 |
Why?
|
| Intestinal Obstruction | 1 | 2004 | 223 | 0.050 |
Why?
|
| Indazoles | 2 | 2015 | 310 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2002 | 376 | 0.050 |
Why?
|
| Endosonography | 1 | 2005 | 551 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 908 | 0.050 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2003 | 402 | 0.050 |
Why?
|
| Laparotomy | 1 | 2002 | 234 | 0.050 |
Why?
|
| Length of Stay | 2 | 2010 | 2004 | 0.050 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2012 | 1335 | 0.040 |
Why?
|
| Incidence | 3 | 2018 | 5821 | 0.040 |
Why?
|
| Rectum | 1 | 2002 | 480 | 0.040 |
Why?
|
| Leucovorin | 2 | 2010 | 345 | 0.040 |
Why?
|
| Models, Biological | 1 | 2008 | 3194 | 0.040 |
Why?
|
| Lung | 1 | 2011 | 3299 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 4048 | 0.040 |
Why?
|
| Ultrasonography | 4 | 2009 | 1933 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3844 | 0.040 |
Why?
|
| Mutation | 4 | 2012 | 15911 | 0.040 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 605 | 0.040 |
Why?
|
| Risk Factors | 3 | 2021 | 17875 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 1436 | 0.040 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 2664 | 0.040 |
Why?
|
| Colon | 1 | 2002 | 659 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2014 | 749 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2002 | 522 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2006 | 2062 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5588 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 1564 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 690 | 0.040 |
Why?
|
| Child, Preschool | 4 | 2013 | 17028 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 1822 | 0.040 |
Why?
|
| Piperazines | 1 | 2007 | 2145 | 0.040 |
Why?
|
| Clusterin | 1 | 2017 | 28 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 255 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 530 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 7383 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2017 | 127 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2006 | 1485 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 224 | 0.040 |
Why?
|
| Needles | 1 | 1997 | 107 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2017 | 2310 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2015 | 1570 | 0.030 |
Why?
|
| Infant | 3 | 2013 | 13982 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1239 | 0.030 |
Why?
|
| Anatomic Landmarks | 1 | 2016 | 51 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 84 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 1997 | 159 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2018 | 424 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2019 | 1042 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2010 | 1825 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2014 | 1565 | 0.030 |
Why?
|
| Role | 1 | 2014 | 47 | 0.030 |
Why?
|
| Genital Neoplasms, Male | 1 | 2014 | 44 | 0.030 |
Why?
|
| Smoking | 1 | 2003 | 2555 | 0.030 |
Why?
|
| Child | 5 | 2018 | 30517 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 2281 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2013 | 1347 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2013 | 100 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 771 | 0.030 |
Why?
|
| Patient Selection | 1 | 2021 | 2026 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 266 | 0.030 |
Why?
|
| Glutamates | 1 | 2013 | 134 | 0.030 |
Why?
|
| Guanine | 1 | 2013 | 157 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 9039 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 543 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 2330 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 483 | 0.030 |
Why?
|
| Texas | 2 | 2015 | 6436 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2021 | 6766 | 0.030 |
Why?
|
| Polyethylene Glycols | 2 | 2008 | 654 | 0.030 |
Why?
|
| Quality of Life | 1 | 2006 | 4774 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 56 | 0.030 |
Why?
|
| Cisplatin | 2 | 2010 | 2496 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 64 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2014 | 592 | 0.020 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 225 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5566 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 1293 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 156 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2238 | 0.020 |
Why?
|
| Urography | 1 | 2010 | 57 | 0.020 |
Why?
|
| United States | 3 | 2018 | 15834 | 0.020 |
Why?
|
| Primates | 1 | 2011 | 128 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 7663 | 0.020 |
Why?
|
| Calcification, Physiologic | 1 | 2010 | 55 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2363 | 0.020 |
Why?
|
| Kidney Pelvis | 1 | 2010 | 114 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 565 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7913 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2010 | 177 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2010 | 2122 | 0.020 |
Why?
|
| Polymers | 1 | 2011 | 222 | 0.020 |
Why?
|
| Dizziness | 1 | 2009 | 43 | 0.020 |
Why?
|
| Femur | 1 | 2010 | 161 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 870 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2006 | 2271 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2009 | 242 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 792 | 0.020 |
Why?
|
| Urothelium | 1 | 2010 | 264 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2011 | 713 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 1247 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4491 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 632 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 201 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1278 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 432 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2008 | 91 | 0.020 |
Why?
|
| Ataxia | 1 | 2009 | 183 | 0.020 |
Why?
|
| Mice | 4 | 2010 | 35586 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 2010 | 257 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 1428 | 0.020 |
Why?
|
| Octreotide | 1 | 2008 | 131 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 540 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1571 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 467 | 0.020 |
Why?
|
| Ipilimumab | 1 | 2011 | 759 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 443 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 2588 | 0.020 |
Why?
|
| Chelating Agents | 1 | 2007 | 130 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 257 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2008 | 502 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2007 | 242 | 0.020 |
Why?
|
| Peptic Ulcer Hemorrhage | 1 | 2006 | 36 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 495 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 333 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2012 | 2357 | 0.020 |
Why?
|
| Gold | 1 | 2007 | 267 | 0.020 |
Why?
|
| Digestive System | 1 | 2006 | 121 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2319 | 0.020 |
Why?
|
| Adiposity | 1 | 2007 | 238 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 341 | 0.020 |
Why?
|
| Critical Illness | 1 | 2010 | 739 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2011 | 1580 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 516 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2006 | 264 | 0.010 |
Why?
|
| Hospitalization | 1 | 2013 | 2168 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2013 | 1697 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 1006 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2009 | 796 | 0.010 |
Why?
|
| Pelvic Exenteration | 1 | 2005 | 112 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2010 | 2846 | 0.010 |
Why?
|
| Survivors | 1 | 2009 | 1022 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2004 | 247 | 0.010 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2004 | 87 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2004 | 213 | 0.010 |
Why?
|
| Bile Duct Neoplasms | 1 | 2008 | 501 | 0.010 |
Why?
|
| Cholangiocarcinoma | 1 | 2008 | 503 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2010 | 3144 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1690 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 724 | 0.010 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2006 | 706 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 886 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2008 | 1564 | 0.010 |
Why?
|
| Lymphoma | 1 | 2010 | 1520 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 3176 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 2045 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 1757 | 0.010 |
Why?
|
| Prostatectomy | 1 | 2005 | 1003 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2007 | 4329 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2007 | 5759 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 2826 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 1458 | 0.010 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 471 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 1825 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 2904 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 4000 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 2003 | 1049 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 1589 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2008 | 2450 | 0.010 |
Why?
|
| Recurrence | 1 | 2006 | 4875 | 0.010 |
Why?
|
| Registries | 1 | 2003 | 2209 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 6238 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 4957 | 0.010 |
Why?
|